Posts Tagged ‘Patient Adherence’

From the MedX Mainstage to the TSX (Toronto Stock Exchange)

Looking back on MEMOTEXT’s accomplishments this fall

Posted on December 2, 2015 by Noah Nemoy

This autumn has been an exciting time for MEMOTEXT. In September our Founder and President Amos Adler had the opportunity to be a main stage speaker at Stanford Medicine X 2015. Presenting the abstract: “Using Disparate Data to Personalize Digital Health Behavior Change Interventions” Amos rocked the crowd explaining the MEMOTEXT methodology. He had a fantastic time at the event and the “Cat pics + health data = behavior change” line got a substantial amount of press coverage.

READ MORE

Click Bait for Your Health: How a Toronto Startup Uses Digital Engagement to Increase Medication Adherence

Posted on November 20, 2015 by Amos Adler

Using digital engagement to increase medication adherence is our novel solution to a complex problem. With non-adherence caused by multiple factors unique to each individual patient, a-one-size-fits-all-solution can’t work and won’t work. Instead, at MEMOTEXT we personalize each patient’s support program. By encouraging patient input, adapting to changes in mood and lifestyle, we can develop a medication adherence and support program that works best.

READ MORE

If I had $290 billion: Breaking Down the Cost of Medication Compliance

Posted on November 05, 2015 by Noah Nemoy

Medication Compliance is one of the biggest costs to worldwide healthcare systems. 50% of all patients do not take their medication as prescribed and this costs the U.S. healthcare system alone $290 billion per year. That’s a pretty massive figure that can be interpreted in several ways.

We can start by breaking down that $290 billion to show exactly how low compliance rates create such a huge cost:

READ MORE

MEMOTEXT Founder and President Amos Adler to Present at Stanford Medicine X 2015

Abstract: “Using Disparate Data to Personalize Digital Health Behavior Change Interventions” to be presented at conference main stage

Toronto, ON September 16, 2015 – MEMOTEXT is pleased to announce that our Founder and President Amos Adler will be a main stage speaker at Stanford Medicine X 2015. Running from September 23-27 in the heart of Silicon Valley, Medicine X is a catalyst for sharing new ideas on the intersection of healthcare and emerging technologies. Hosted by Stanford University, Medicine X brings together both business and academia for a 4 day conversation on the future of healthcare.

READ MORE

We’re Going to Stanford!

MEMOTEXT Founder and President Amos Adler to Present at Stanford Medicine X 2015

Posted on July 23, 2015 by Noah Nemoy

MEMOTEXT is pleased to announce that our President and Founder Amos Adler will be speaking at Stanford Medicine X 2015! Running from September 23-27 in the heart of Silicon Valley, Medicine X is a catalyst for sharing new ideas on the intersection of healthcare and emerging technologies. Hosted by Stanford University, Medicine X brings together both business and academia for a 4 day conversation on the future of healthcare.

READ MORE

MEMOTEXT Makes the Top 20

MEMOTEXT is named by HIT Consultant as one of the Top 20 Canadian Digital Health Technology Start-Ups to Watch

Posted on July 23, 2015 by Noah Nemoy

Earlier this month HIT Consultant, released their list of the Top 20 Canadian digital health companies to lookout for. The companies on the list were selected for their potential for growth and represented disparate areas of digital health, including digital health solutions, diagnostics, and patient centred care. MEMOTEXT managed to not only make the Top 20, but was also one of the Top 10 digital health start-ups in Eastern Canada, and the only company of the 20 with an exclusive focus on patient adherence.

READ MORE

MEMOTEXT Pitches PAAS2015

Posted on July 6, 2015 by Noah Nemoy

Last week, MEMOTEXT Founder and President Amos Adler was invited to both attend and present at the 14th Annual Patient Adherence & Access Summit, or PAAS2015 in Philadelphia. While there MEMOTEXT had the opportunity to share in the discussion of the latest issues regarding patient adherence and access, to medication.

READ MORE

MEMOTEXT Presents at the Pittsburgh Science of Medication Adherence:

Director of Scientific Development Bill Simpson unveils our new BAM adherence metric

Posted on June 26, 2015 by Bill Simpson

2 weeks ago MEMOTEXT had the privilege of presenting our new Balanced Adherence Metric (BAM) at the inaugural Science of Medication Adherence Conference (SMA2015), hosted by the University of Pittsburgh Centre for Pharmaceutical Policy and Prescribing.

READ MORE

MEMOTEXT and PerformRx Co-Present HealthNHand’s PBM and Health Plan Enrolled- Asthma Patient Adherence Case Study

Posted on June 17, 2015 by Noah Nemoy

On Monday morning, MEMOTEXT’s Founder and President Amos Adler and PerformRx’s Director of Drug Therapy Management Programs & Outcomes Lauren C. Megargell, had the honor to jointly present the results of our HealthNHandSM asthma adherence program to the The Digital Transformation of Patient Care: New Avenues for Pharma Growth Seminar. The seminar was organized by the Consulate General of Canada in New York’s Canadian Technology Accelerator (CTA) Health IT Philadelphia as part of BIO2015.

READ MORE

MEMOTEXT Corp. Validating New Adherence Metric: The Balanced Adherence Metric (BAM)

MEMOTEXT to present at both Washington D.C.’s Health Datapalooza 2015 and Pittsburgh’s SMA 2015 this week

Washington, D.C. June 1, 2015 – MEMOTEXT Corp. announces today the upcoming presentation of the Balanced Adherence Metric (BAM). The BAM will be presented tomorrow by MEMOTEXT’s Director of Scientific Development Bill Simpson, Ph.D. Candidate in Neuroscience, at the inaugural Science of Medication Adherence conference (SMA 2015) at the University of Pittsburgh. MEMOTEXT also has a delegation at Washington D.C.’s Health Datapalooza 2015 including Founder and President of MEMOTEXT Amos Adler, M.Sc. Health Datapalooza 2015 runs from today until Wednesday and MEMOTEXT will be present for the entire duration.

READ MORE
Back to Top